Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 168 articles: HTML format

Single Articles

July 2020
1. DESMEDT C, Fornili M, Clatot F, Demicheli R, et al
   Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.
   J Clin Oncol. 2020 Jul 2:JCO1901771. doi: 10.1200/JCO.19.01771.
   PubMed     Abstract available
   
   
   
2. CHLEBOWSKI RT, Aragaki AK, Prentice RL
   Dietary Moderation and Deaths From Breast Cancer.
   J Clin Oncol. 2020 Jul 2:JCO2001218. doi: 10.1200/JCO.20.01218.
   PubMed    
   
   
   June 2020
3. PISTILLI B, Paci A, Ferreira AR, Di Meglio A, et al
   Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
   J Clin Oncol. 2020 Jun 22:JCO1901758. doi: 10.1200/JCO.19.01758.
   PubMed     Abstract available
   
   
   
4. TAKAMIZAWA S, Ishiki H, Shimoi T, Shimizu M, et al
   Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.
   J Clin Oncol. 2020 Jun 9:JCO2000789. doi: 10.1200/JCO.20.00789.
   PubMed    
   
   
   May 2020
5. LIN NU, Borges V, Anders C, Murthy RK, et al
   Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
   J Clin Oncol. 2020 May 29:JCO2000775. doi: 10.1200/JCO.20.00775.
   PubMed     Abstract available
   
   
   
6. TORRES MA, Horst KC, Freedman GM
   Postmastectomy and Regional Nodal Radiation for Breast Cancer.
   J Clin Oncol. 2020 May 22:JCO1902908. doi: 10.1200/JCO.19.02908.
   PubMed    
   
   
   
7. MITTENDORF EA, Bellon JR, King TA
   Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery.
   J Clin Oncol. 2020 May 22:JCO1902891. doi: 10.1200/JCO.19.02891.
   PubMed    
   
   
   
8. HEPEL JT, Wazer DE
   Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer.
   J Clin Oncol. 2020 May 22:JCO1902594. doi: 10.1200/JCO.19.02594.
   PubMed    
   
   
   
9. SMITH BD, Goetz MP, Boughey JC
   Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.
   J Clin Oncol. 2020 May 22:JCO1903036. doi: 10.1200/JCO.19.03036.
   PubMed     Abstract available
   
   
   
10. RECHT A
    Whole-Breast Irradiation Is the Preferred Standard of Care for the Majority of Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902388. doi: 10.1200/JCO.19.02388.
    PubMed    
    
    
    
11. SHAITELMAN SF, Jeruss JS, Pusic AL
    Oncoplastic Surgery in the Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902795. doi: 10.1200/JCO.19.02795.
    PubMed    
    
    
    
12. KUHL CK, Lehman C, Bedrosian I
    Imaging in Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1903257. doi: 10.1200/JCO.19.03257.
    PubMed    
    
    
    
13. SCHNITT SJ, Moran MS, Giuliano AE
    Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact.
    J Clin Oncol. 2020 May 22:JCO1903213. doi: 10.1200/JCO.19.03213.
    PubMed    
    
    
    
14. MCLAUGHLIN SA, Brunelle CL, Taghian A
    Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.
    J Clin Oncol. 2020 May 22:JCO1902896. doi: 10.1200/JCO.19.02896.
    PubMed    
    
    
    
15. HAFFTY BG, Euhus DM, Pierce LJ
    Genetic Factors in the Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902859. doi: 10.1200/JCO.19.02859.
    PubMed    
    
    
    
16. SMITH BD, Mittendorf EA, Haffty BG
    Multidisciplinary Locoregional Management of Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO2000483. doi: 10.1200/JCO.20.00483.
    PubMed    
    
    
    
17. BUCHHOLZ TA, Ali S, Hunt KK
    Multidisciplinary Management of Locoregional Recurrent Breast Cancer.
    J Clin Oncol. 2020 May 22:JCO1902806. doi: 10.1200/JCO.19.02806.
    PubMed    
    
    
    
18. HERSHMAN DL, Unger JM, Hillyer GC, Moseley A, et al
    Randomized Trial of Text Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Early-Stage Breast Cancer: SWOG S1105.
    J Clin Oncol. 2020 May 5:JCO1902699. doi: 10.1200/JCO.19.02699.
    PubMed     Abstract available
    
    
    April 2020
19. USUI Y, Ishiki H, Shimomura A, Satomi E, et al
    Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.
    J Clin Oncol. 2020 Apr 30:JCO1903406. doi: 10.1200/JCO.19.03406.
    PubMed    
    
    
    
20. TARANTINO P, Hamilton E, Tolaney SM, Cortes J, et al
    HER2-Low Breast Cancer: Pathological and Clinical Landscape.
    J Clin Oncol. 2020 Apr 24:JCO1902488. doi: 10.1200/JCO.19.02488.
    PubMed    
    
    
    
21. JAVOR E, Lucijanic M, Skelin M
    Dietary Supplement Use and Patient Outcomes in High-Risk Early-Stage Breast Cancer.
    J Clin Oncol. 2020 Apr 21:JCO2000091. doi: 10.1200/JCO.20.00091.
    PubMed    
    
    
    
22. LI J, Yu K, Pang D, Wang C, et al
    Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
    J Clin Oncol. 2020 Apr 10:JCO1902474. doi: 10.1200/JCO.19.02474.
    PubMed     Abstract available
    
    
    
23. WAGNER LI, Gray RJ, Sparano JA, Whelan TJ, et al
    Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
    J Clin Oncol. 2020 Apr 9:JCO1901866. doi: 10.1200/JCO.19.01866.
    PubMed     Abstract available
    
    
    
24. HORTOBAGYI GN
    Breast Cancer: 45 Years of Research and Progress.
    J Clin Oncol. 2020 Apr 7:JCO2000199. doi: 10.1200/JCO.20.00199.
    PubMed    
    
    
    
25. TUNG NM, Boughey JC, Pierce LJ, Robson ME, et al
    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    J Clin Oncol. 2020 Apr 3:JCO2000299. doi: 10.1200/JCO.20.00299.
    PubMed     Abstract available
    
    
    March 2020
26. LIGIBEL JA
    Could the Women's Health Initiative Breathe New Life Into Breast Cancer Prevention?
    J Clin Oncol. 2020 Mar 9:JCO2000148. doi: 10.1200/JCO.20.00148.
    PubMed    
    
    
    
27. GANZ PA, Van Dyk K
    Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy.
    J Clin Oncol. 2020 Mar 6:JCO2000336. doi: 10.1200/JCO.20.00336.
    PubMed    
    
    
    
28. YADAV S, Hu C, Hart SN, Boddicker N, et al
    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    J Clin Oncol. 2020 Mar 3:JCO1902190. doi: 10.1200/JCO.19.02190.
    PubMed     Abstract available
    
    
    February 2020
29. TUNG N, Arun B, Hacker MR, Hofstatter E, et al
    TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
    J Clin Oncol. 2020 Feb 25:JCO1903292. doi: 10.1200/JCO.19.03292.
    PubMed     Abstract available
    
    
    
30. DELALOGE S, Piccart M, Rutgers E, Litiere S, et al
    Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
    J Clin Oncol. 2020 Feb 21:JCO1901371. doi: 10.1200/JCO.19.01371.
    PubMed     Abstract available
    
    
    
31. MODI S, Park H, Murthy RK, Iwata H, et al
    Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    J Clin Oncol. 2020 Feb 14:JCO1902318. doi: 10.1200/JCO.19.02318.
    PubMed     Abstract available
    
    
    
32. HASSETT MJ, Somerfield MR, Baker ER, Cardoso F, et al
    Management of Male Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Feb 14:JCO1903120. doi: 10.1200/JCO.19.03120.
    PubMed     Abstract available
    
    
    
33. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Pan K, et al
    Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial.
    J Clin Oncol. 2020 Feb 7:JCO1900435. doi: 10.1200/JCO.19.00435.
    PubMed     Abstract available
    
    
    January 2020
34. RAYSON D
    Camouflage.
    J Clin Oncol. 2020;38:281-282.
    PubMed    
    
    
    
35. ALLISON KH, Hammond MEH, Dowsett M, McKernin SE, et al
    Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
    J Clin Oncol. 2020 Jan 13:JCO1902309. doi: 10.1200/JCO.19.02309.
    PubMed     Abstract available
    
    
    
36. GEIERSBACH KB, Meyer RG, Sill DR, Mounajjed T, et al
    Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future.
    J Clin Oncol. 2020;38:175-176.
    PubMed    
    
    
    
37. HENRY NL, Andre F, Ismaila N, Somerfield MR, et al
    Reply to A. Katz.
    J Clin Oncol. 2020;38:102-103.
    PubMed    
    
    
    
38. KATZ A
    Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?
    J Clin Oncol. 2020;38:102.
    PubMed    
    
    
    December 2019
39. HAYES DF, Rae JM
    Pharmacogenomics and Endocrine Therapy in Breast Cancer.
    J Clin Oncol. 2019 Dec 27:JCO1903119. doi: 10.1200/JCO.19.03119.
    PubMed    
    
    
    
40. AMBROSONE CB, Zirpoli GR, Hutson AD, McCann WE, et al
    Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
    J Clin Oncol. 2019 Dec 19:JCO1901203. doi: 10.1200/JCO.19.01203.
    PubMed     Abstract available
    
    
    
41. SCHMID P, Abraham J, Chan S, Wheatley D, et al
    Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
    J Clin Oncol. 2019 Dec 16:JCO1900368. doi: 10.1200/JCO.19.00368.
    PubMed     Abstract available
    
    
    
42. DUMAS A, Vaz Luis I, Bovagnet T, El Mouhebb M, et al
    Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
    J Clin Oncol. 2019 Dec 13:JCO1901726. doi: 10.1200/JCO.19.01726.
    PubMed     Abstract available
    
    
    
43. FEHRENBACHER L, Cecchini RS, Geyer CE Jr, Rastogi P, et al
    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
    J Clin Oncol. 2019 Dec 10:JCO1901455. doi: 10.1200/JCO.19.01455.
    PubMed     Abstract available
    
    
    
44. TAMURA K, Imamura CK, Takano T, Saji S, et al
    CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
    J Clin Oncol. 2019 Dec 10:JCO1901412. doi: 10.1200/JCO.19.01412.
    PubMed     Abstract available
    
    
    
45. POORVU PD, Gelber SI, Rosenberg SM, Ruddy KJ, et al
    Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
    J Clin Oncol. 2019 Dec 6:JCO1901959. doi: 10.1200/JCO.19.01959.
    PubMed     Abstract available
    
    
    
46. LLUCH A, Barrios CH, Torrecillas L, Ruiz-Borrego M, et al
    Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
    J Clin Oncol. 2019 Dec 5:JCO1900904. doi: 10.1200/JCO.19.00904.
    PubMed     Abstract available
    
    
    
47. VARSHAVSKY-YANOVSKY AN, Goldstein LJ
    Role of Capecitabine in Early Breast Cancer.
    J Clin Oncol. 2019 Dec 5:JCO1902946. doi: 10.1200/JCO.19.02946.
    PubMed    
    
    
    
48. JAYASEKERA J, Mandelblatt JS
    Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.
    J Clin Oncol. 2019 Dec 5:JCO1901525. doi: 10.1200/JCO.19.01525.
    PubMed    
    
    
    
49. HE W, Grassmann F, Eriksson M, Eliasson E, et al
    CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.
    J Clin Oncol. 2019 Dec 4:JCO1901535. doi: 10.1200/JCO.19.01535.
    PubMed     Abstract available
    
    
    October 2019
50. SHARMA P, Barlow WE, Godwin AK, Parkes EE, et al
    Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    J Clin Oncol. 2019 Oct 28:JCO1900693. doi: 10.1200/JCO.19.00693.
    PubMed     Abstract available
    
    
    
51. CHUMSRI S, Li Z, Serie DJ, Mashadi-Hossein A, et al
    Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.
    J Clin Oncol. 2019 Oct 17:JCO1900443. doi: 10.1200/JCO.19.00443.
    PubMed     Abstract available
    
    
    
52. SJOSTROM M, Chang SL, Fishbane N, Davicioni E, et al
    Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1900761. doi: 10.1200/JCO.19.00761.
    PubMed     Abstract available
    
    
    
53. LAMBERTINI M, Blondeaux E, Perrone F, Del Mastro L, et al
    Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2019 Oct 16:JCO1902242. doi: 10.1200/JCO.19.02242.
    PubMed     Abstract available
    
    
    September 2019
54. HOWIE LJ, Singh H, Bloomquist E, Wedam S, et al
    Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis.
    J Clin Oncol. 2019 Sep 27:JCO1802217. doi: 10.1200/JCO.18.02217.
    PubMed     Abstract available
    
    
    
55. KIM HA, Lee JW, Nam SJ, Park BW, et al
    Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
    J Clin Oncol. 2019 Sep 16:JCO1900126. doi: 10.1200/JCO.19.00126.
    PubMed     Abstract available
    
    
    
56. VISVANATHAN K, Fabian CJ, Bantug E, Brewster AM, et al
    Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.
    J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472.
    PubMed     Abstract available
    
    
    August 2019
57. HINDIE E
    Skipping the Lymphoscintigraphy Step During Sentinel Node Procedures in Breast Cancer: What Information Are We Missing?
    J Clin Oncol. 2019 Aug 29:JCO1901612. doi: 10.1200/JCO.19.01612.
    PubMed    
    
    
    
58. LITTON JK, Scoggins ME, Hess KR, Adrada BE, et al
    Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
    J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304.
    PubMed     Abstract available
    
    
    
59. JIMENEZ RB, Hickey S, DePauw N, Yeap BY, et al
    Phase II Study of Proton Beam Radiation Therapy for Patients With Breast Cancer Requiring Regional Nodal Irradiation.
    J Clin Oncol. 2019 Aug 26:JCO1802366. doi: 10.1200/JCO.18.02366.
    PubMed     Abstract available
    
    
    
60. ABRAHAM J, Montero AJ, Jankowitz RC, Salkeni MA, et al
    Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
    J Clin Oncol. 2019 Aug 23:JCO1900858. doi: 10.1200/JCO.19.00858.
    PubMed     Abstract available
    
    
    
61. MA F, Ouyang Q, Li W, Jiang Z, et al
    Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    J Clin Oncol. 2019 Aug 20:JCO1900108. doi: 10.1200/JCO.19.00108.
    PubMed     Abstract available
    
    
    
62. CESPEDES FELICIANO EM, Chen WY, Bradshaw PT, Prado CM, et al
    Adipose Tissue Distribution and Cardiovascular Disease Risk Among Breast Cancer Survivors.
    J Clin Oncol. 2019 Aug 1:JCO1900286. doi: 10.1200/JCO.19.00286.
    PubMed     Abstract available
    
    
    July 2019
63. MUSS HB, Polley MC, Berry DA, Liu H, et al
    Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
    J Clin Oncol. 2019 Jul 24:JCO1900647. doi: 10.1200/JCO.19.00647.
    PubMed     Abstract available
    
    
    
64. ROSS M, Geyer CE Jr
    Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
    J Clin Oncol. 2019 Jul 15:JCO1900877. doi: 10.1200/JCO.19.00877.
    PubMed    
    
    
    
65. MOSKOWITZ CS, Chou JF, Neglia JP, Partridge AH, et al
    Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1802219. doi: 10.1200/JCO.18.02219.
    PubMed     Abstract available
    
    
    
66. OEFFINGER KC, Ford JS, Moskowitz CS, Chou JF, et al
    Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study.
    J Clin Oncol. 2019 Jul 1:JCO1900547. doi: 10.1200/JCO.19.00547.
    PubMed     Abstract available
    
    
    June 2019
67. HINDIE E, Groheux D
    Interim [(18)F]Fluorodeoxyglucose-Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 28:JCO1900776. doi: 10.1200/JCO.19.00776.
    PubMed    
    
    
    
68. RAJAGOPAL PS, Catenacci DVT, Olopade OI
    The Time for Mainstreaming Germline Testing for Patients With Breast Cancer Is Now.
    J Clin Oncol. 2019 Jun 27:JCO1900160. doi: 10.1200/JCO.19.00160.
    PubMed    
    
    
    
69. TAYLOR A, Tischkowitz M
    Caveat Emptor: The Perils of Panel Testing in Hereditary Breast Cancer.
    J Clin Oncol. 2019 Jun 27:JCO1900122. doi: 10.1200/JCO.19.00122.
    PubMed    
    
    
    
70. COPUR MS, Jonglertham P, Zusag T
    Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?
    J Clin Oncol. 2019 Jun 27:JCO1900064. doi: 10.1200/JCO.19.00064.
    PubMed    
    
    
    
71. GOETZ MP, Suman VJ, Nakamura Y, Kiyotani K, et al
    Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.
    J Clin Oncol. 2019 Jun 18:JCO1900504. doi: 10.1200/JCO.19.00504.
    PubMed    
    
    
    
72. HENRY NL, Somerfield MR, Abramson VG, Ismaila N, et al
    Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    J Clin Oncol. 2019 Jun 17:JCO1900948. doi: 10.1200/JCO.19.00948.
    PubMed     Abstract available
    
    
    
73. KANTOR ED, Romano ME
    Phthalate Exposure From Prescription Medications and Breast Cancer Risk.
    J Clin Oncol. 2019 Jun 7:JCO1901003. doi: 10.1200/JCO.19.01003.
    PubMed    
    
    
    
74. CONFORTI F, Pala L
    Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
    J Clin Oncol. 2019 Jun 7:JCO1900559. doi: 10.1200/JCO.19.00559.
    PubMed    
    
    
    
75. HURVITZ SA, Martin M, Jung KH, Huang CS, et al
    Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
    J Clin Oncol. 2019 Jun 3:JCO1900882. doi: 10.1200/JCO.19.00882.
    PubMed     Abstract available
    
    
    
76. WOLFF AC, Tung NM, Carey LA
    Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Jun 3:JCO1901159. doi: 10.1200/JCO.19.01159.
    PubMed    
    
    
    May 2019
77. ANDRE F, Ismaila N, Henry NL, Somerfield MR, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
    J Clin Oncol. 2019 May 31:JCO1900945. doi: 10.1200/JCO.19.00945.
    PubMed     Abstract available
    
    
    
78. SMITH TG, Troeschel AN, Castro KM, Arora NK, et al
    Perceptions of Patients With Breast and Colon Cancer of the Management of Cancer-Related Pain, Fatigue, and Emotional Distress in Community Oncology.
    J Clin Oncol. 2019 May 17:JCO1801579. doi: 10.1200/JCO.18.01579.
    PubMed     Abstract available
    
    
    
79. FABIAN CJ
    Will a Low-Dose Option Improve Uptake of Tamoxifen for Breast Cancer Risk Reduction?
    J Clin Oncol. 2019 May 13:JCO1900656. doi: 10.1200/JCO.19.00656.
    PubMed    
    
    
    
80. UNTCH M, Jackisch C, Schneeweiss A, Schmatloch S, et al
    NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
    J Clin Oncol. 2019 May 13:JCO1801842. doi: 10.1200/JCO.18.01842.
    PubMed     Abstract available
    
    
    
81. EHRHARDT MJ, Howell CR, Hale K, Baassiri MJ, et al
    Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
    J Clin Oncol. 2019 May 10:JCO1801099. doi: 10.1200/JCO.18.01099.
    PubMed     Abstract available
    
    
    
82. KUEMMEL S, Holtschmidt J, Gerber B, Von der Assen A, et al
    Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial.
    J Clin Oncol. 2019 May 1:JCO1802092. doi: 10.1200/JCO.18.02092.
    PubMed     Abstract available
    
    
    April 2019
83. YU KD, Shao ZM
    Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
    J Clin Oncol. 2019 Apr 29:JCO1802468. doi: 10.1200/JCO.18.02468.
    PubMed    
    
    
    
84. AHERN TP, Broe A, Lash TL, Cronin-Fenton DP, et al
    Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort Study.
    J Clin Oncol. 2019 Apr 17:JCO1802202. doi: 10.1200/JCO.18.02202.
    PubMed     Abstract available
    
    
    
85. KURIAN AW, Ward KC, Howlader N, Deapen D, et al
    Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854.
    PubMed     Abstract available
    
    
    
86. FOLDI J, O'Meara T, Marczyk M, Sanft T, et al
    Defining Risk of Late Recurrence in Early-Stage Estrogen Receptor-Positive Breast Cancer: Clinical Versus Molecular Tools.
    J Clin Oncol. 2019 Apr 3:JCO1801933. doi: 10.1200/JCO.18.01933.
    PubMed    
    
    
    
87. TOLANEY SM, Guo H, Pernas S, Barry WT, et al
    Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Clin Oncol. 2019 Apr 2:JCO1900066. doi: 10.1200/JCO.19.00066.
    PubMed     Abstract available
    
    
    March 2019
88. CHANDARLAPATY S, Razavi P
    Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors.
    J Clin Oncol. 2019 Mar 28:JCO1900090. doi: 10.1200/JCO.19.00090.
    PubMed    
    
    
    
89. FREEDMAN RA, Gelman RS, Anders CK, Melisko ME, et al
    TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    J Clin Oncol. 2019 Mar 12:JCO1801511. doi: 10.1200/JCO.18.01511.
    PubMed     Abstract available
    
    
    February 2019
90. REGAN MM, Fleming GF, Walley B, Francis PA, et al
    Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
    J Clin Oncol. 2019 Feb 27:JCO1802433. doi: 10.1200/JCO.18.02433.
    PubMed    
    
    
    
91. TURNER NC, Liu Y, Zhu Z, Loi S, et al
    Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2019 Feb 26:JCO1800925. doi: 10.1200/JCO.18.00925.
    PubMed     Abstract available
    
    
    
92. NITZ U, Gluz O, Clemens M, Malter W, et al
    West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    J Clin Oncol. 2019 Feb 20:JCO1800028. doi: 10.1200/JCO.18.00028.
    PubMed     Abstract available
    
    
    
93. ATEMA V, van Leeuwen M, Kieffer JM, Oldenburg HSA, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2019 Feb 14:JCO1800655. doi: 10.1200/JCO.18.00655.
    PubMed     Abstract available
    
    
    
94. PAN K, Bosserman LD, Chlebowski RT
    Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
    J Clin Oncol. 2019 Feb 11:JCO1801360. doi: 10.1200/JCO.18.01360.
    PubMed    
    
    
    
95. DOWSETT M, Turner N
    Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk.
    J Clin Oncol. 2019 Feb 11:JCO1801412. doi: 10.1200/JCO.18.01412.
    PubMed    
    
    
    
96. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2019 Feb 5:JCO2018787986. doi: 10.1200/JCO.2018.78.7986.
    PubMed     Abstract available
    
    
    January 2019
97. HAMY AS, Tury S, Wang X, Gao J, et al
    Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.
    J Clin Oncol. 2019 Jan 31:JCO1800636. doi: 10.1200/JCO.18.00636.
    PubMed     Abstract available
    
    
    
98. ARASU VA, Miglioretti DL, Sprague BL, Alsheik NH, et al
    Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
    J Clin Oncol. 2019 Jan 9:JCO1800378. doi: 10.1200/JCO.18.00378.
    PubMed     Abstract available
    
    
    December 2018
99. DELLAPASQUA S, Gray KP, Munzone E, Rubino D, et al
    Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
    J Clin Oncol. 2018 Dec 27:JCO1800296. doi: 10.1200/JCO.18.00296.
    PubMed     Abstract available
    
    
    
100. BEITSCH PD, Whitworth PW, Hughes K, Patel R, et al
     Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
     J Clin Oncol. 2018 Dec 7:JCO1801631. doi: 10.1200/JCO.18.01631.
     PubMed     Abstract available
     
     
     
101. MILLIRON KJ, Griggs JJ
     Advances in Genetic Testing in Patients With Breast Cancer, High-Quality Decision Making, and Responsible Resource Allocation.
     J Clin Oncol. 2018 Dec 7:JCO1801952. doi: 10.1200/JCO.18.01952.
     PubMed    
     
     
     
102. JOHNSTON S, Puhalla S, Wheatley D, Ring A, et al
     Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
     J Clin Oncol. 2018 Dec 6:JCO1801624. doi: 10.1200/JCO.18.01624.
     PubMed     Abstract available
     
     
     November 2018
103. RUHSTALLER T, Giobbie-Hurder A, Colleoni M, Jensen MB, et al
     Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
     J Clin Oncol. 2018 Nov 26:JCO1800440. doi: 10.1200/JCO.18.00440.
     PubMed     Abstract available
     
     
     
104. BURSTEIN HJ, Lacchetti C, Anderson H, Buchholz TA, et al
     Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 Nov 19:JCO1801160. doi: 10.1200/JCO.18.01160.
     PubMed     Abstract available
     
     
     October 2018
105. MANDELBLATT JS, Small BJ, Luta G, Hurria A, et al
     Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study.
     J Clin Oncol. 2018 Oct 3:JCO1800140. doi: 10.1200/JCO.18.00140.
     PubMed     Abstract available
     
     
     September 2018
106. CRUZ C, Llop-Guevara A, Garber JE, Arun BK, et al
     Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
     J Clin Oncol. 2018 Sep 21:JCO2018786558. doi: 10.1200/JCO.2018.78.6558.
     PubMed     Abstract available
     
     
     
107. BARDIA A, Parton M, Kummel S, Estevez LG, et al
     Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
     J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392.
     PubMed     Abstract available
     
     
     
108. SEIDMAN AD, Bordeleau L, Fehrenbacher L, Barlow WE, et al
     National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.
     J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242.
     PubMed     Abstract available
     
     
     
109. BEAU AB, Andersen PK, Vejborg I, Lynge E, et al
     Limitations in the Effect of Screening on Breast Cancer Mortality.
     J Clin Oncol. 2018 Sep 4:JCO2018780270. doi: 10.1200/JCO.2018.78.0270.
     PubMed     Abstract available
     
     
     August 2018
110. GINSBURG O, Brennan P
     Genetic Testing for Breast Cancer in the Era of Multigene Panels: Can We Make an Impact on Population Health?
     J Clin Oncol. 2018 Aug 21:JCO2018793307. doi: 10.1200/JCO.2018.79.3307.
     PubMed    
     
     
     
111. ZHENG Y, Walsh T, Gulsuner S, Casadei S, et al
     Inherited Breast Cancer in Nigerian Women.
     J Clin Oncol. 2018 Aug 21:JCO2018783977. doi: 10.1200/JCO.2018.78.3977.
     PubMed     Abstract available
     
     
     
112. RIMAWI M, Ferrero JM, de la Haba-Rodriguez J, Poole C, et al
     First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase I
     J Clin Oncol. 2018 Aug 14:JCO2017767863. doi: 10.1200/JCO.2017.76.7863.
     PubMed     Abstract available
     
     
     July 2018
113. PARKER PA, Peterson SK, Shen Y, Bedrosian I, et al
     Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer.
     J Clin Oncol. 2018 Jul 25:JCO2018786442. doi: 10.1200/JCO.2018.78.6442.
     PubMed     Abstract available
     
     
     
114. MILLER KD, O'Neill A, Gradishar W, Hobday TJ, et al
     Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
     J Clin Oncol. 2018 Jul 24:JCO2018792028. doi: 10.1200/JCO.2018.79.2028.
     PubMed     Abstract available
     
     
     
115. HOUSTON TP, Ostroff JS
     Cardiovascular Risk Factors and Breast Cancer.
     J Clin Oncol. 2018 Jul 23:JCO1800041. doi: 10.1200/JCO.18.00041.
     PubMed    
     
     
     
116. HU JJ, Urbanic JJ, Case LD, Takita C, et al
     Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.
     J Clin Oncol. 2018 Jul 10:JCO2017771790. doi: 10.1200/JCO.2017.77.1790.
     PubMed     Abstract available
     
     
     June 2018
117. RAMAKRISHNA N, Temin S, Chandarlapaty S, Crews JR, et al
     Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
     J Clin Oncol. 2018 Jun 25:JCO2018792713. doi: 10.1200/JCO.2018.79.2713.
     PubMed     Abstract available
     
     
     
118. GIORDANO SH, Temin S, Chandarlapaty S, Crews JR, et al
     Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.
     J Clin Oncol. 2018 Jun 25:JCO2018792697. doi: 10.1200/JCO.2018.79.2697.
     PubMed     Abstract available
     
     
     
119. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
     Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
     J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
     PubMed     Abstract available
     
     
     
120. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
     Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
     J Clin Oncol. 2018 Jun 3:JCO2018789909. doi: 10.1200/JCO.2018.78.9909.
     PubMed     Abstract available
     
     
     May 2018
121. WOLFF AC, Hammond MEH, Allison KH, Harvey BE, et al
     Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 May 30:JCO2018778738. doi: 10.1200/JCO.2018.77.8738.
     PubMed     Abstract available
     
     
     
122. FASCHING PA, Loibl S, Hu C, Hart SN, et al
     BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
     J Clin Oncol. 2018 May 23:JCO2017772285. doi: 10.1200/JCO.2017.77.2285.
     PubMed     Abstract available
     
     
     
123. TAYLOR C, McGale P, Bronnum D, Correa C, et al
     Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data.
     J Clin Oncol. 2018 May 23:JCO2017776351. doi: 10.1200/JCO.2017.77.6351.
     PubMed     Abstract available
     
     
     
124. THAVENDIRANATHAN P, Abdel-Qadir H, Fischer HD, Liu Y, et al
     Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
     J Clin Oncol. 2018 May 23:JCO2018779736. doi: 10.1200/JCO.2018.77.9736.
     PubMed     Abstract available
     
     
     
125. DENDULURI N, Chavez-MacGregor M, Telli ML, Eisen A, et al
     Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
     J Clin Oncol. 2018 May 22:JCO2018788604. doi: 10.1200/JCO.2018.78.8604.
     PubMed     Abstract available
     
     
     
126. WANG L, Hong BY, Kennedy SA, Chang Y, et al
     Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies.
     J Clin Oncol. 2018 May 14:JCO2017773663. doi: 10.1200/JCO.2017.77.3663.
     PubMed     Abstract available
     
     
     
127. LAMBERTINI M, Moore HCF, Leonard RCF, Loibl S, et al
     Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
     J Clin Oncol. 2018 May 2:JCO2018780858. doi: 10.1200/JCO.2018.78.0858.
     PubMed     Abstract available
     
     
     April 2018
128. SHERMAN KA, Przezdziecki A, Alcorso J, Kilby CJ, et al
     Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial.
     J Clin Oncol. 2018 Apr 24:JCO2017763318. doi: 10.1200/JCO.2017.76.3318.
     PubMed     Abstract available
     
     
     
129. HAMOOD R, Hamood H, Merhasin I, Keinan-Boker L, et al
     Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.
     J Clin Oncol. 2018 Apr 24:JCO2017763524. doi: 10.1200/JCO.2017.76.3524.
     PubMed     Abstract available
     
     
     
130. DEGNIM AC, Winham SJ, Frank RD, Pankratz VS, et al
     Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.
     J Clin Oncol. 2018 Apr 20:JCO2017759480. doi: 10.1200/JCO.2017.75.9480.
     PubMed     Abstract available
     
     
     
131. DOWSETT M, Sestak I, Regan MM, Dodson A, et al
     Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
     J Clin Oncol. 2018 Apr 20:JCO2017764258. doi: 10.1200/JCO.2017.76.4258.
     PubMed     Abstract available
     
     
     
132. WHEELER SB, Spencer JC, Pinheiro LC, Carey LA, et al
     Financial Impact of Breast Cancer in Black Versus White Women.
     J Clin Oncol. 2018 Apr 18:JCO2017776310. doi: 10.1200/JCO.2017.77.6310.
     PubMed     Abstract available
     
     
     
133. KORNBLUM N, Zhao F, Manola J, Klein P, et al
     Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
     J Clin Oncol. 2018 Apr 17:JCO2017769331. doi: 10.1200/JCO.2017.76.9331.
     PubMed     Abstract available
     
     
     
134. WANG SY, Dang W, Richman I, Mougalian SS, et al
     Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.
     J Clin Oncol. 2018 Apr 16:JCO2017765941. doi: 10.1200/JCO.2017.76.5941.
     PubMed     Abstract available
     
     
     
135. REINER AS, Sisti J, John EM, Lynch CF, et al
     Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
     J Clin Oncol. 2018 Apr 5:JCO2017773424. doi: 10.1200/JCO.2017.77.3424.
     PubMed     Abstract available
     
     
     March 2018
136. HERSHMAN DL, Till C, Shen S, Wright JD, et al
     Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.
     J Clin Oncol. 2018 Mar 27:JCO2017774414. doi: 10.1200/JCO.2017.77.4414.
     PubMed     Abstract available
     
     
     
137. MASSARWEH SA, Sledge GW, Miller DP, McCullough D, et al
     Molecular Characterization and Mortality From Breast Cancer in Men.
     J Clin Oncol. 2018 Mar 27:JCO2017768861. doi: 10.1200/JCO.2017.76.8861.
     PubMed     Abstract available
     
     
     
138. JAGSI R, Griffith KA, Bellon JR, Woodward WA, et al
     Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.
     J Clin Oncol. 2018 Mar 20:JCO2017772665. doi: 10.1200/JCO.2017.77.2665.
     PubMed     Abstract available
     
     
     
139. UNTCH M, von Minckwitz G, Gerber B, Schem C, et al
     Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
     J Clin Oncol. 2018 Mar 15:JCO2017759175. doi: 10.1200/JCO.2017.75.9175.
     PubMed     Abstract available
     
     
     
140. KATZ SJ, Ward KC, Hamilton AS, Mcleod MC, et al
     Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
     J Clin Oncol. 2018 Mar 12:JCO2017762369. doi: 10.1200/JCO.2017.76.2369.
     PubMed     Abstract available
     
     
     
141. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
     US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
     J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
     PubMed     Abstract available
     
     
     February 2018
142. WHARAM JF, Zhang F, Lu CY, Wagner AK, et al
     Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment.
     J Clin Oncol. 2018 Feb 28:JCO2017752501. doi: 10.1200/JCO.2017.75.2501.
     PubMed     Abstract available
     
     
     
143. ZARDAVAS D, Te Marvelde L, Milne RL, Fumagalli D, et al
     Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
     J Clin Oncol. 2018 Feb 22:JCO2017748301. doi: 10.1200/JCO.2017.74.8301.
     PubMed     Abstract available
     
     
     
144. WAPNIR IL, Price KN, Anderson SJ, Robidoux A, et al
     Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
     J Clin Oncol. 2018 Feb 14:JCO2017765719. doi: 10.1200/JCO.2017.76.5719.
     PubMed     Abstract available
     
     
     
145. KENNEDY L, Bhatta S, Hechmati G, Buchanan J, et al
     Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
     J Clin Oncol. 2018 Feb 1:JCO2017770115. doi: 10.1200/JCO.2017.77.0115.
     PubMed    
     
     
     January 2018
146. NEUMAN HB, Schumacher JR, Francescatti AB, Adesoye T, et al
     Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01).
     J Clin Oncol. 2018 Jan 31:JCO2017755389. doi: 10.1200/JCO.2017.75.5389.
     PubMed     Abstract available
     
     
     
147. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
     Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
     J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
     PubMed     Abstract available
     
     
     
148. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
     Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
     PubMed     Abstract available
     
     
     
149. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
     PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
     J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
     PubMed     Abstract available
     
     
     
150. HAWLEY ST, Li Y, An LC, Resnicow K, et al
     Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
     J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
     PubMed     Abstract available
     
     
     
151. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
     Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
     J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
     PubMed     Abstract available
     
     
     
152. HOLOWATYJ AN, Cote ML, Ruterbusch JJ, Ghanem K, et al
     Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 17:JCO2017745448. doi: 10.1200/JCO.2017.74.5448.
     PubMed     Abstract available
     
     
     
153. ZIVANOVIC BUJAK A, Dawson SJ
     Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 3:JCO2017765461. doi: 10.1200/JCO.2017.76.5461.
     PubMed    
     
     
     
154. STOVER DG, Parsons HA, Ha G, Freeman SS, et al
     Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.
     J Clin Oncol. 2018 Jan 3:JCO2017760033. doi: 10.1200/JCO.2017.76.0033.
     PubMed     Abstract available
     
     
     December 2017
155. BUTOW PN, Turner J, Gilchrist J, Sharpe L, et al
     Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
     J Clin Oncol. 2017;35:4066-4077.
     PubMed     Abstract available
     
     
     
156. JOHNSTON SRD, Hegg R, Im SA, Park IH, et al
     Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Br
     J Clin Oncol. 2017 Dec 15:JCO2017747824. doi: 10.1200/JCO.2017.74.7824.
     PubMed     Abstract available
     
     
     
157. BLUM JL, Robert N, Andersen J, Favret A, et al
     Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
     J Clin Oncol. 2017 Dec 11:JCO2017753756. doi: 10.1200/JCO.2017.75.3756.
     PubMed    
     
     
     November 2017
158. HENRY NL, Unger JM, Schott AF, Fehrenbacher L, et al
     Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
     J Clin Oncol. 2017 Nov 14:JCO2017746651. doi: 10.1200/JCO.2017.74.6651.
     PubMed     Abstract available
     
     
     
159. HWONG AR, Mangurian C
     Improving Breast Cancer Screening and Care for Women With Severe Mental Illness.
     J Clin Oncol. 2017 Nov 2:JCO2017760462. doi: 10.1200/JCO.2017.76.0462.
     PubMed    
     
     
     October 2017
160. GANZ PA, Romond EH, Cecchini RS, Rastogi P, et al
     Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Pacl
     J Clin Oncol. 2017 Oct 26:JCO2017741165. doi: 10.1200/JCO.2017.74.1165.
     PubMed     Abstract available
     
     
     
161. JEMAL A, Robbins AS, Lin CC, Flanders WD, et al
     Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
     J Clin Oncol. 2017 Oct 16:JCO2017737932. doi: 10.1200/JCO.2017.73.7932.
     PubMed     Abstract available
     
     
     
162. VAN POZNAK C, Somerfield MR, Barlow WE, Biermann JS, et al
     Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
     J Clin Oncol. 2017 Oct 16:JCO2017754614. doi: 10.1200/JCO.2017.75.4614.
     PubMed     Abstract available
     
     
     
163. SHAPIRO CL, Moriarty JP, Dusetzina S, Himelstein AL, et al
     Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
     J Clin Oncol. 2017 Oct 12:JCO2017737437. doi: 10.1200/JCO.2017.73.7437.
     PubMed     Abstract available
     
     
     
164. ASDOURIAN MS, Swaroop MN, Sayegh HE, Brunelle CL, et al
     Association Between Precautionary Behaviors and Breast Cancer-Related Lymphedema in Patients Undergoing Bilateral Surgery.
     J Clin Oncol. 2017 Oct 4:JCO2017737494. doi: 10.1200/JCO.2017.73.7494.
     PubMed     Abstract available
     
     
     
165. GOETZ MP, Toi M, Campone M, Sohn J, et al
     MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
     J Clin Oncol. 2017 Oct 2:JCO2017756155. doi: 10.1200/JCO.2017.75.6155.
     PubMed     Abstract available
     
     
     September 2017
166. WU JW, Azoulay L, Majdan A, Boivin JF, et al
     Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
     J Clin Oncol. 2017 Sep 27:JCO2017734491. doi: 10.1200/JCO.2017.73.4491.
     PubMed     Abstract available
     
     
     
167. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
     Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
     J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
     PubMed     Abstract available
     
     
     February 2017
168. LYMAN GH, Somerfield MR, Bosserman LD, Perkins CL, et al
     Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
     J Clin Oncol. 2017;35:561-564.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: